MSP58 knockdown inhibits the proliferation of esophageal squamous cell carcinoma in vitro and in vivo

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3233-3238

  Xu, Chun Sheng ^a   Zheng, Jian Yong ^a   Zhang, Hai Long ^c   Zhao, Hua Dong ^b   Zhang, Jing ^a   Wu, Guo Qiang ^c   Wu, Lin ^a   Wang, Qing ^b   Wang, Wei Zhong ^a   Zhang, Jian ^a  

^a State Key Laboratory of Cancer Biology   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; MSP58; Small hairpin RNA (shRNA)

Indexed keywords

EID: 84873580812     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3233     Document Type: Article

References (34)

1. Allum WH, Stenning SP, Bancewicz J, et al. (2009). Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27, 5062-7.
2. Anayama T, Furihata M, Takeuchi T, et al. (2001). Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro. Int J Oncol, 18, 151-5.
3. Bader AG, Schneider ML, Bister K, Hartl M. (2001). TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1. (MCRS1). Oncogene, 20, 7524-35.
4. Bos TJ, De Bruyne E, Heirman C, Vanderkerken K. (2009). In search of the most suitable lentiviral shRNA system. Curr Gene Ther, 9, 192-211.
5. Boudreau RL, Davidson BL. (2012). Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods Enzymol, 507, 275-96.
6. Chumakov SP, Kravchenko JE, Prassolov VS, et al. (2010). Efficient downregulation of multiple mRNA targets with a single shRNA-expressing lentiviral vector. Plasmid, 63, 143-9.
7. Davidovic L, Bechara E, Gravel M, et al. (2006). The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. Hum Mol Genet, 15, 1525-38.
8. Ekholm SV, Reed SI. (2000). Regulation of G(1) cyclindependent kinases in the mammalian cell cycle. Curr Opin Cell Biol, 12, 676-84.
9. Enzinger PC, Mayer RJ. (2003). Esophageal cancer. N Engl J Med, 349, 2241-52.
10. Ferrandiz N, Caraballo JM, Garcia-Gutierrez L, et al. (2012). p21 as a Transcriptional Co-Repressor of S-Phase and Mitotic Control Genes. PLoS One, 7, e37759.
11. Hanahan, D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
12. Hartwell LH, Kastan MB. (1994). Cell cycle control and cancer. Science, 266, 1821-8.
13. Howell AS, Lew DJ. (2012). Morphogenesis and the cell cycle. Genetics, 190, 51-77.
14. Ivanova AV, Ivanov SV, Lerman ML. (2005). Association, mutual stabilization, and transcriptional activity of the STRA13 and MSP58 proteins. Cell Mol Life Sci, 62, 471-84.
15. Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
16. Lin DY, Shih HM. (2002). Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration. J Biol Chem, 277, 25446-56.
17. Lin W, Zhang J, Liu X, et al. (2009). RNAi-mediated inhibition of MSP58 decreases tumour growth, migration and invasion in a human glioma cell line. J Cell Mol Med, 13, 4608-22.
18. Matrai J, Chuah MK, VandenDriessche T. (2010). Recent advances in lentiviral vector development and applications. Mol Ther, 18, 477-90.
19. Matsuoka S, Edwards MC, Bai C, et al. (1995). p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev, 9, 650-62.
20. Okumura K, Zhao M, Depinho RA, et al. (2005). Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA, 102, 2703-6.
21. Pai SI, Lin YY, Macaes B, et al. (2006). Prospects of RNA interference therapy for cancer. Gene Ther, 13, 464-77.
22. Pickens A, Orringer MB. (2003). Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg, 76, S1367-9.
23. Polyak K, Lee MH, Erdjument-Bromage H, et al. (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
24. Ren Y, Busch RK, Perlaky L, Busch H. (1998). The 58-kDa microspherule protein. (MSP58), a nucleolar protein, interacts with nucleolar protein p120. Eur J Biochem, 253, 734-42.
25. Shi H, Chen S, Jin H, et al. (2009). Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1-cyclin-dependent kinase 4-p21 pathway. Cancer Sci, 100, 1585-90.
26. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
27. Sjoquist KM, Burmeister BH, Smithers BM, et al. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol, 12, 681-92.
28. Stoner GD, Gupta A. (2001). Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 22, 1737-46.
29. Sumimoto H, Kawakami Y. (2007). Lentiviral vector-mediated RNAi and its use for cancer research. Future Oncol, 3, 655-64.
30. Swanton C. (2004). Cell-cycle targeted therapies. Lancet Oncol, 5, 27-36.
31. Xiong Y, Hannon GJ, Zhang H, et al. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-4.
32. Xu XH, Peng XH, Yu P, et al. (2012). Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials. Asian Pac J Cancer Prev, 13, 103-10.
33. Yu X, Zhang T, Zhang H, et al. (2010). Comparison of lifestyle and living environment among high risk immigrant and low risk host residents: implications for esophageal cancer etiology. Asian Pac J Cancer Prev, 11, 1827-31.
34. Zhang J, Liu J, Li X, et al. (2007). The physical and functional interaction of NDRG2 with MSP58 in cells. Biochem Biophys Res Commun, 352, 6-11.